The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility - PubMed (original) (raw)
. 1995 Jul 14;270(28):16886-94.
doi: 10.1074/jbc.270.28.16886.
Affiliations
- PMID: 7622505
- DOI: 10.1074/jbc.270.28.16886
Free article
The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility
T H Bugge et al. J Biol Chem. 1995.
Free article
Abstract
The urokinase-type plasminogen activator receptor (uPAR) gene was disrupted in mice in order to explore the role of cell surface-associated plasminogen activation in development and hemostasis. Homozygous, uPAR-/- mice were born and survived to adulthood with no overt phenotypic abnormalities. There was no indication of loss of fetal animals based on the Mendelian pattern of transmission of the mutant uPAR gene. uPAR-/- mice carried no detectable uPAR in lung, spleen, and other tissues when measured both immunologically by Western blot analysis and functionally by ligand cross-linking analyses. In addition, activated peritoneal macrophages collected from uPAR-/- mice failed to promote plasminogen activation in vitro. The loss of the receptor also resulted in a redistribution of uPA in some tissues but had no impact on pro-uPA activation in the urogenital tract. Thus, in the absence of other challenging factors such as infection, injury, or other functional deficits, uPAR deficiency does not compromise fertility, development, or hemostasis. These mice provide a means to test the proposed function of uPA/uPAR in wound repair, atherogenesis, and tumor cell invasion in vivo.
Similar articles
- Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator.
Bugge TH, Flick MJ, Danton MJ, Daugherty CC, Romer J, Dano K, Carmeliet P, Collen D, Degen JL. Bugge TH, et al. Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5899-904. doi: 10.1073/pnas.93.12.5899. Proc Natl Acad Sci U S A. 1996. PMID: 8650190 Free PMC article. - Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.
Quax PH, Grimbergen JM, Lansink M, Bakker AH, Blatter MC, Belin D, van Hinsbergh VW, Verheijen JH. Quax PH, et al. Arterioscler Thromb Vasc Biol. 1998 May;18(5):693-701. doi: 10.1161/01.atv.18.5.693. Arterioscler Thromb Vasc Biol. 1998. PMID: 9598826 - Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T, Behrendt N, Ploug M. Plesner T, et al. Stem Cells. 1997;15(6):398-408. doi: 10.1002/stem.150398. Stem Cells. 1997. PMID: 9402652 Review. - Biological significance of the expression of urokinase-type plasminogen activator receptors (uPARs) in brain tumors.
Mohanam S, Gladson CL, Rao CN, Rao JS. Mohanam S, et al. Front Biosci. 1999 Feb 15;4:D178-87. doi: 10.2741/mohanam. Front Biosci. 1999. PMID: 9989951 Review.
Cited by
- Emerging connections between GPI-anchored proteins and their extracellular carriers in colorectal cancer.
Tutanov OS, Glass SE, Coffey RJ. Tutanov OS, et al. Extracell Vesicles Circ Nucl Acids. 2023 Jun;4(2):195-217. doi: 10.20517/evcna.2023.17. Epub 2023 May 18. Extracell Vesicles Circ Nucl Acids. 2023. PMID: 37840781 Free PMC article. - Targeted imaging of uPAR expression in vivo with cyclic AE105 variants.
Leth JM, Newcombe EA, Grønnemose AL, Jørgensen JT, Qvist K, Clausen AS, Knudsen LBS, Kjaer A, Kragelund BB, Jørgensen TJD, Ploug M. Leth JM, et al. Sci Rep. 2023 Oct 11;13(1):17248. doi: 10.1038/s41598-023-43934-w. Sci Rep. 2023. PMID: 37821532 Free PMC article. - Targeting cellular senescence to combat cancer and ageing.
Wang C, Hao X, Zhang R. Wang C, et al. Mol Oncol. 2022 Sep;16(18):3319-3332. doi: 10.1002/1878-0261.13266. Epub 2022 Jun 20. Mol Oncol. 2022. PMID: 35674055 Free PMC article. Review. - The Plasminogen-Activator Plasmin System in Physiological and Pathophysiological Angiogenesis.
Ismail AA, Shaker BT, Bajou K. Ismail AA, et al. Int J Mol Sci. 2021 Dec 29;23(1):337. doi: 10.3390/ijms23010337. Int J Mol Sci. 2021. PMID: 35008762 Free PMC article. Review. - The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and Opportunities.
Metrangolo V, Ploug M, Engelholm LH. Metrangolo V, et al. Cancers (Basel). 2021 Oct 27;13(21):5376. doi: 10.3390/cancers13215376. Cancers (Basel). 2021. PMID: 34771541 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous